Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. by Mason, MD et al.
Final Report of the Intergroup Randomized Study of
Combined Androgen-Deprivation Therapy Plus
Radiotherapy Versus Androgen-Deprivation Therapy Alone
in Locally Advanced Prostate Cancer
Malcolm D. Mason, Wendy R. Parulekar, Matthew R. Sydes, Michael Brundage, Peter Kirkbride,
Mary Gospodarowicz, Richard Cowan, Edmund C. Kostashuk, John Anderson, Gregory Swanson,
Mahesh K.B. Parmar, Charles Hayter, Gordana Jovic, Andrea Hiltz, John Hetherington, Jinka Sathya,
James B.P. Barber, Michael McKenzie, Salah El-Sharkawi, Luis Souhami, P.D. John Hardman,
Bingshu E. Chen, and Padraig Warde
Author affiliations appear at the end of
this article.
Published online ahead of print at
www.jco.org on February 17, 2015.
Supported by National Cancer Institute
Grant No. CA077202, Canadian Cancer
Society Research Institute Grants No.
015469 and No. 021039, United King-
dom Medical Research Council Grant
No. G9805643, and the United King-
dom National Cancer Research
Network.
Presented at the 48th Annual Meeting
of the American Society of Clinical
Oncology, June 1-5, 2012, Chicago, IL.
Clinical trial information: NCT00002633
Terms in blue are defined in the glos-
sary, found at the end of this article
and online at www.jco.org.
Authors’ disclosures of potential
conflicts of interest are found in the
article online at www.jco.org. Author
contributions are found at the end of
this article.
Written on behalf of the NCIC Clinical
Trials Group PR.3/Medical Research
Council PR07/Intergroup T94-0110
investigators.
Corresponding author: Malcolm D.
Mason, MD, FRCP, FRCF, FSB, Cardiff
University School of Medicine, Velindre
Hospital, Whitchurch, Cardiff CF14 2TL,
United Kingdom; e-mail: masonmd@cardiff.
ac.uk.
© 2015 American Society of Clinical
Oncology. Licensed under the Creative
Commons Attribution 3.0 License.
aaaaaa
0732-183X/15/3399-1/$20.00
DOI: 10.1200/JCO.2014.57.7510
A B S T R A C T
Purpose
We have previously reported that radiotherapy (RT) added to androgen-deprivation therapy (ADT)
improves survival in men with locally advanced prostate cancer. Here, we report the prespecified
final analysis of this randomized trial.
Patients and Methods
NCIC Clinical Trials Group PR.3/Medical Research Council PR07/Intergroup T94-0110 was a
randomized controlled trial of patients with locally advanced prostate cancer. Patients with T3-4,
N0/Nx, M0 prostate cancer or T1-2 disease with either prostate-specific antigen (PSA) of more
than 40 g/L or PSA of 20 to 40 g/L plus Gleason score of 8 to 10 were randomly assigned to
lifelong ADT alone or to ADTRT. The RT dose was 64 to 69 Gy in 35 to 39 fractions to the
prostate and pelvis or prostate alone. Overall survival was compared using a log-rank test stratified
for prespecified variables.
Results
One thousand two hundred five patients were randomly assigned between 1995 and 2005,
602 to ADT alone and 603 to ADTRT. At a median follow-up time of 8 years, 465 patients had
died, including 199 patients from prostate cancer. Overall survival was significantly improved
in the patients allocated to ADTRT (hazard ratio [HR], 0.70; 95% CI, 0.57 to 0.85; P  .001).
Deaths from prostate cancer were significantly reduced by the addition of RT to ADT (HR,
0.46; 95% CI, 0.34 to 0.61; P  .001). Patients on ADTRT reported a higher frequency of
adverse events related to bowel toxicity, but only two of 589 patients had grade 3 or greater
diarrhea at 24 months after RT.
Conclusion
This analysis demonstrates that the previously reported benefit in survival is maintained at a
median follow-up of 8 years and firmly establishes the role of RT in the treatment of men with
locally advanced prostate cancer.
J Clin Oncol © 2015 American Society of Clinical Oncology. Licensed under the Creative
Commons Attribution 3.0 License: http://creativecommons.org/licenses/by/3.0/
INTRODUCTION
Prostate cancer is themost commoncancerdiagnosed
in men in the Western Hemisphere, with approxi-
mately 899,000 patients diagnosed and258,000deaths
worldwide in2008.1Patientswith locallyadvanceddis-
ease, defined as stage categories T3-4,N0, andM0, are
still prevalent in regions where the use of prostate-
specific antigen (PSA) screening is notwidespread.2
Previous uncertainties about the roles of radio-
therapy (RT) and androgen-deprivation therapy
(ADT)3,4 have been greatly clarified after the publica-
tionofrandomizedtrialsdemonstrating thebenefitsof
ADT added to RT and the benefits of RT added to
ADT.5-7 Three reported randomized trials compared
ADTalonewith toADTplusRT.Thepresent trialwas
the largest of these and was developed by the NCIC
ClinicalTrialsGroupincollaborationwiththeMedical
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ResearchCouncil and theNational Cancer InstituteUSCancer Therapy
EvaluationProgram.The interimanalysisof this intergrouptrialhasbeen
reported previously8 and showed a significant overall survival (OS) im-
provement for patients treated with ADTRT (hazard ratio [HR], 0.77;
95% CI, 0.61 to 0.98; P  .033) and improvement in disease-specific
survival (DSS). The final, preplanned analysis presented here reports on
the longer-term survival outcomes and toxicity. Quality-of-life analyses
are reported byBrundage et al.8a
PATIENTS AND METHODS
The study design has been previously described in detail.8 Patients were ran-
domly assigned to ADT alone or to ADTRT. Eligible patients had locally
advanced disease, initially defined as T3-4, N0,M0. In 1999, the entry criteria
werebroadened to includepatientswith localized (T1-2)buthigh-riskdisease,
defined either as a PSA of more than 40 g/L or PSA of 20 to 40 g/L plus a
Gleason score of 8 to 10. Pelvic node imaging was not mandatory unless only
the prostate was to be irradiated, rather than the whole pelvis. Surgical lymph
node staging before randomassignmentwas permitted andhad to be negative
for nodal disease. No previous therapy for prostate cancer was allowed, but
random assignment was permitted within a 12-week window after starting
first-line ADT.
The primary objective was to determine whether the addition of RT to
ADT prolonged OS, defined as time from random assignment to death from
any cause or censoring at last follow-up. Secondary end points were time to
progression(TTP),DSS,qualityof life, toxicity, andsymptomatic local control
(defined as surgical interventions for symptomatic local disease).
Diseaseprogressionwasdefinedas thefirstof anyof the followingevents:
biochemical progression, local progression, development of metastatic dis-
ease, or death fromprostate cancer. For theper-protocol analysis, biochemical
progression was defined by two consecutive PSA readings of more than 10
ng/mL in patients whose PSA nadir was 4 ng/mL. In patients whose PSA
nadirwas greater than 4ng/mL, biochemical progressionwas defined as aPSA
level of more than 10 ng/mL and 20% above the baseline reading. In addition
to this prespecifieddefinition,we analyzedbiochemical progression according
to the American Society for Radiation Oncology Phoenix criteria.9 Local
progressionwas defined either after histologic confirmation or after the devel-
opment of ureteric obstruction. Distant progression was defined by imaging.
Patients were randomly assigned using a straight minimization strat-
egy,10 stratifiedbycenter, initialPSA level (20v20 to50v50g/L), choice
of hormonal therapy (luteinizing hormone–releasing hormone [LHRH] ago-
nist v orchiectomy), method of lymph node staging (clinical v surgical v not
done), Gleason score ( 8 v 8 to 10), and prior hormonal therapy.
ADT consisted of either bilateral orchiectomy or LHRH agonists (plus 2
weeks of oral antiandrogen to cover flare), according to patient and physician
preference, and was continued for life. RT was to start within 8 weeks after
randomassignment andwas given to thewhole pelvis, to a dose of 45Gy in 25
fractions, followed by a further 20 to 24 Gy to the prostate alone in 10 to 12
fractions. The total treatment timewas 7 to 7.5weeks. If the treating physician
felt that a patient was unsuitable for whole pelvic RT or if histologically
negative lymph nodes had been demonstrated, RT to the prostate alone, to a
doseof64 to69Gy in35 to39 fractions,waspermitted.PelvicRTwasdelivered
using a four-field box technique to cover the prostate, seminal vesicles, and
internal andexternal iliac lymphnodes.Theprostate volumeencompassed the
prostate andperiprostatic tissueswith amargin at the investigatingphysician’s
discretion. Patients in Canada underwent real-time review of their RT imple-
mentation. The dose distributions, treatment prescription sheets and simula-
tor films for Canadian patients were reviewed by one author (C.H.) before
treatmentorat latestwithin3daysof startof treatment, andrecommendations
for change, if necessary,were faxedback to the prescribingphysicianwithin 24
hours. After the completion of RT, copies of all completed prescription sheets
were sent for review to ascertain that the treatment was delivered according to
protocol.Thedosewas specifiedat the intersectionof thebeamaxes, according
to the guidelines of the International Commission on Radiation Units.11 The
study received the required local and national ethics committee approvals; all
patients signed an informed consent document.
The original study design mandated accrual of 650 patients to the trial,
based on an assumed 10-year survival of 35% for patients treated with ADT
only, todetect a10%improvement in10-year survival (HRof0.76,80%power
using a one-sided 5% level test). In September 2002, after 688 patients had
been recruited, the protocol was amended because of a low event rate. The
revised statistical parameters assumed a 57% survival rate at 10 years in the
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Fig 1. CONSORT diagram. ADT, androgen-deprivation therapy; RT, radiotherapy.
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control arm, 80%power, and an overall 2.5% level one-sided test to detect the
sameHRof0.76,whichwould translate toanabsolute8.4%increase in10-year
survival. This required a total of 421 deaths for the final analysis, taking two
planned interim analyses into account. On the basis of the type I error spend-
ing function as proposed by DeMets and Lan,12 the prespecified significance
level for final analysis was P  .035 (two-sided) to maintain the overall
significant level of two-sided P  .05. According to these specifications, the
estimated sample size for the study was 1,200.
OSwasdeterminedusing theKaplan-Meierproduct-limitmethod13and
compared using a log-rank test stratified for initial PSA level, choice of hor-
monal therapy, method of lymph node staging, Gleason score, and prior
hormonal therapy. Two Cox model analyses were used. First, HRs and CIs
were estimated (Coxmodel 1).14 TheDSS rates were estimated by cumulative
incidence. The analyses were performed with the use of SAS software, version
9.2 (SAS Institute, Cary, NC). Second, a Cox proportional hazardsmodel was
used to assess the treatment effect while adjusting for known important prog-
nostic factors in addition to the prespecified stratification factors (Coxmodel
2). These were region (North America v rest of world), initial PSA level ( 20
v20 to50 v50g/L vmissing),Gleason score (8 v8 to10 vmissing), prior
hormone therapy (excluding orchiectomy; yes v no), choice of hormonal
therapy (orchiectomy v LHRHagonist), method of lymph node staging (clin-
ical [no computed tomography] v radiologic [computed tomography nega-
tive] v surgical dissection v not done or missing), age ( v 65 years), and
orchiectomy versus LHRH.TTPwas defined as the time from randomassign-
ment to the date of the first documented disease progression or death from
prostate cancer.
Table 1. Baseline Demographics and Clinical Characteristics
Demographic or Clinical Characteristic
ADT (n  602) ADTRT (n  603) Total (N  1,205)
No. of Patients % No. of Patients % No. of Patients %
Age, years
 65 134 22.3 132 21.9 266 22.1
 65 468 77.7 471 78.1 939 77.9
Median 69.7 69.7 69.7
Range 50-79.8 46.3-80.3 46.3-80.3
ECOG performance status
0 474 78.7 469 77.8 943 78.3
1 119 19.8 126 20.9 245 20.3
2 9 1.5 8 1.3 17 1.4
Lymph node staging
Clinical 427 70.9 422 70.0 849 70.5
Radiologic 50 8.3 53 8.8 103 8.5
Surgical 12 2.0 17 2.8 29 2.4
Not done 113 18.8 111 18.4 224 18.6
T stage
Missing 1 0.2 1 0.1
T2 76 12.6 71 11.8 147 12.2
T3 499 82.9 501 83.1 1000 83.0
T4 27 4.5 30 5.0 57 4.7
Rectal exam
Done 586 97.3 588 97.5 1174 97.4
Not done 16 2.7 15 2.5 31 2.6
Results of rectal examination
Abnormal 161 26.7 162 26.9 323 26.8
Normal 19 3.2 19 3.2 38 3.2
Unknown/missing 422 70.1 422 70.0 844 70.0
Region of patients
Northern America 180 29.9 181 30.0 361 30.0
MRC 422 70.1 422 70.0 844 70.0
Initial PSA level, g/L
 20 223 37.0 216 35.8 439 36.4
20-50 229 38.0 231 38.3 460 38.2
 50 150 24.9 156 25.9 306 25.4
Gleason score
Missing 6 1.0 3 0.5 9 0.7
 8 380 63.1 381 63.2 761 63.2
8-10 216 35.9 219 36.3 435 36.1
ADT before random assignment
No 314 52.2 315 52.2 629 52.2
Yes 288 47.8 288 47.8 576 47.8
Choice of hormonal therapy
LHRH 562 93.4 562 93.2 1124 93.3
Bilateral orchiectomy 40 6.6 41 6.8 81 6.7
Abbreviations: ADT, androgen-deprivation therapy; ECOG, Eastern Cooperative Oncology Group; LHRH, luteinizing hormone–releasing hormone; MRC, Medical
Research Council; PSA, prostate-specific antigen; RT, radiotherapy.
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Toxicity wasmeasured using the NCICClinical Trials Group Expanded
Common Toxicity Criteria. Information on quality of life is presented by
Brundage et al.8a
RESULTS
Between 1995 and 2005, 1,205 patients were randomly assigned (Fig
1). Trial participants were well matched in terms of their baseline
characteristics (Table 1). Theirmedian age was 70 years. Eighty-seven
percent of patients had locally advanced (T3-4) disease, 63% of pa-
tients had a PSA of more than 20g/L, and 18% had a Gleason score
of more than 8. The database contained data up to and including
December 31, 2010, and included 465 reported deaths. The median
follow-up time was 8 years (range, 0 to 15.2 years). Ninety-four per-
centofpatients included in theanalysishaddataavailable in the2years
preceding the clinical cutoff date.
Of the 603 patients randomly assigned to ADTRT, 586 (97%)
received RT, and 13 did not receive RT; in four patients, it was un-
knownwhether or not RTwas received. Of the 586 patients known to
have received RT, 43 received doses less than 65 Gy, and 10 received
doses greater than 69 Gy. Thus, 88% of the patients allocated to the
ADTRTarmreceiveddosesbetween65and69Gy.Nine(1%)of602
patients randomly assigned to ADT alone received RT, as defined by
irradiation to the pelvis of more than 50 Gy within 1 year of random
assignment and without evidence of disease progression. LHRH ago-
nistswereused in 1,105patients (92%), andbilateral orchiectomywas
performed in 93 patients (8%), with no evidence of differences in
proportions between the two arms.
OS
There were 260 deaths reported in patients treated with ADT
alone and 205 deaths in patients treatedwithADTRT. The addition
of RT led to a 30% reduction in the risk of death (HR, 0.70, based on
Cox model 1; 95% CI, 0.57 to 0.85; P .001; Fig 2). The median OS
time was 9.7 years (95% CI, 8.8 to 10.5 years) for patients on the
ADT-alone arm,whereas itwas 10.9 years (95%CI, 10.0 to 12.8 years)
forpatients on theADTRTarm.The10-yearOS ratewas 49%(95%
CI, 44% to 54%) for patients on the ADT arm, whereas it was 55%
(95% CI, 49% to 60%) for patients on the ADTRT arm. A multi-
variable Cox model confirmed the effect of treatment, independent
from other variables, with a P .0011 in favor of the ADTRT arm.
The adjusted HR of ADTRT versus ADT alone was 0.74 (95% CI,
0.61 to 0.87, based on Cox model 2). Both PSA level ( 50 v  20
g/L) and Gleason score (8 to 10 v 8) were significant prognostic
factors for OS.
DSS
Analysis of DSS indicated an excess of deaths caused by prostate
cancer inpatients treatedwithADTalone (Table2).Acompeting risks
analysis indicated a significant reduction in the risk of death from
prostate cancer in patients treatedwith ADTRT (HR, 0.46; 95%CI,
0.34 to 0.61;P .001; Fig 3). Therewas no evidence of any differences
in deaths from other causes (P  .58; Table 2). Sensitivity analyses
were performed to test the impact of potential inaccuracy in investi-
gator assignment of cause of death. In each case, the reduction in risks
of death from prostate cancer in RT-treated patients was confirmed,
with P .001
Nonfatal End Points
Disease progression. Using the prespecified definition of bio-
chemical progression, the 10-year disease progression–free rate was
HR, 0.70 (95% CI, 0.57 to 0.85); P < .001
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Fig 2. Overall survival (OS). ADT, androgen-deprivation therapy; HR, hazard
ratio; RT, radiotherapy.
Table 2. Causes of Death
Cause of
Death
ADT
(n  260)
ADTRT
(n  205)
Total
(n  465)
No. of
Patients %
No. of
Patients %
No. of
Patients %
Prostate cancer 134 52 65 32 199 43
Cardiac/stroke 37 14 33 16 70 15
Other cancer 31 12 44 17 75 16
Pneumonia 11 4 11 9 22 5
Other 31 12 34 21 65 14
Unknown 16 6 18 5 34 7
Alive 342 398 740
Abbreviations: ADT, androgen-deprivation therapy; RT, radiotherapy.
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Fig 3. Deaths from prostate cancer. ADT, androgen-deprivation therapy; RT,
radiotherapy.
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46% (95% CI, 41% to 51%) for patients on the ADT-alone arm and
74% (95% CI, 68% to 78%) for patients on the ADTRT arm. The
HRforTTPon theADTRTarmversus theADT-alonearmwas0.31
(95%CI, 0.25 to 0.39; Fig 4A).
Using the American Society for Radiation Oncology Phoenix
definition of biochemical progression, the 10-year biochemical
progression-free rate was 27% (95%CI, 23% to 32%) for patients on
the ADT-alone arm, whereas it was 63% (95% CI, 57% to 68%) for
patients on theADTRTarm.TheHRforTTPon theADTRTarm
versus the ADT armwas 0.31 (95%CI, 0.27 to 0.37).
Toxicity. The five most frequent grade 3 or higher treatment-
related toxicitieswere impotence/libido (29%forADTalone and33%
for ADTRT; P .17), hot flushes (8% for ADT alone and 5% for
ADTRT; P .10), urinary frequency (4% for ADT alone and 7%
for ADTRT; P  .13), ischemia (3% for ADT alone and 5% for
ADTRT;P .09), andhypertension (3%forADTalone and4%for
ADTRT;P .54). Therewasno evidence of a difference in reported
cardiovascular toxicities between the two arms. Bowel-related adverse
events were more frequent in the ADTRT arm compared with the
ADT arm; most were grade 1 and 2. The rate of bowel adverse events
greater thangrade 3 at 24monthswasnegligible (twoof 589 assessable
patients in the ADTRT arm (Table 3).
Effect of RT Field
Usingdataprospectively reportedby investigators,weperformed
exploratoryposthocanalyses (uncorrected formultiple comparisons)
to examine the effects of RT field among patients allocated to the
ADTRT arm, stratified by region, PSA, Gleason score, choice of
hormone therapy, lymph node staging, and prior hormone therapy.
Patients planned for pelvic irradiation (n 420, 72%) showed a trend
toward improvedOScomparedwithprostate-onlyRT(n166,28%;
HR, 0.70; 95% CI, 0.45 to 1.09; P .12). The other efficacy analyses
were as follows: for TTP, the HR was 0.77 (95% CI, 0.44 to 1.34;
stratified log-rank P .35), and for DSS, the HR was 0.53 (95% CI,
0.25 to 1.13; P .098).
DISCUSSION
These results confirm the previous, interim findings from our ran-
domized controlled trial,8 with RT improving both overall and pros-
tate cancer–specific outcomes (DSS, TTP) when added to ADT in
men with locally advanced disease. Furthermore, this was achieved
without major detriment in terms of long-term toxicity. Our results
concur with those from other trials in similar groups of patients. The
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Fig 4. Time to disease progression (TTP; A) using prespecified definition of biochemical progression and (B) using American Society for Radiation Oncology Phoenix
definition of biochemical progression. ADT, androgen-deprivation therapy; RT, radiotherapy.
Table 3. Bowel-Related Adverse Events at 24 Months
Toxicity
No. of Patients
ADT (n  606) ADTRT (n  589) Total
Any Grade 1-2 Grade 3-5 Any Grade 1-2 Grade 3-5 Any Grade 1-2 Grade 3-5
Diarrhea 87 14 0 223 32 2 310 46 2
Flatulence 20 1 1 37 7 0 57 8 1
Bleeding 50 5 0 133 41 0 183 46 0
Pain 62 12 1 79 10 0 141 22 1
Proctitis 43 4 0 119 19 0 162 23 0
Abbreviations: ADT, androgen-deprivation therapy; RT, radiotherapy.
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Swedish Prostate Cancer Group (SPCG) study SPCG-715 showed a
similar reduction in overall mortality (HR, 0.68) and disease-specific
mortality (HR, 0.44) for the addition of RT to flutamide. A study
(ClinicalTrials.gov identifier: NCT01122121) by the French collabor-
ative group in 264 patients with T3-4 disease reported a significant
improvement in progression-free survival with the addition of RT to
ADT.16 Median OS times had not been reached in that study, and no
improvement in OS was detected; however, this trial was relatively
small and was powered only to detect a difference in 5-year
progression-free survival and not a difference in OS.
Our results are noteworthy for a number of reasons. First, they
indicate that the benefits seen for RT in the context of ADT with
flutamide (in the SPCG-7 study) are also seen with LHRH agonist
therapy or surgical castration. Second, our patient population repre-
sents a higher risk group than in SPCG-7; the Swedish group had
pathologic confirmation of N0 status if the PSA was greater than 11
ng/mL (2% of our study), 20% had T1-2 disease (10% in our study),
60% had a PSA of less than 20 ng/mL (37% of our study), and the
maximum allowed PSA level was 70 ng/mL (unlimited in our study),
although 75%of patients hadWHOgrade 1 or 2 tumors, (81% in our
study had Gleason score  7). Third, the median follow-up in our
study was 8 years compared with 7.6 years in the SPCG-7 study.
The RT technique used in our trial reflects the prevailing treat-
mentphilosophiesof the time.The studypredatedoutcomedata from
randomized trials of dose-escalated RT, and the RT doses used here
aremodest bymodern standards.17-19Whether dose escalation in this
settingmight achieve superioroutcomes even to those reportedhere is
a matter for speculation. Data from dose-escalation studies suggest
that biochemical control might be as much as two-fold better for RT
doses greater than 70Gy,20 and there is no evidence that patients with
T3-4 disease do not realize such benefits from dose escalation.17,20 A
recent study using ADTplus dose-escalated RT (80Gy in 40 fractions
or equivalent) in 168 patients with high-risk prostate cancer reported
a biochemical progression-free rate of 79% at 5 years.21
Another unanswered question relates to the optimum field of
RT. This question is still unresolved despite several randomized
trials.22-24 Our nonrandomized, post hoc exploratory subgroup anal-
ysis indicates a trend toward improved outcomewith larger field size,
a finding that requires confirmation in a rigorously conducted phase
III randomized controlled trial. These resultsmust be interpretedwith
caution because of biases inherent with selection of RT field in our
study (ie, the influence of comorbidities or other patient factors that
may confound the efficacy analyses) and the potential formore toxic-
ity associated with a wider field of treatment delivery. Ongoing trials,
such as the United KingdomPIVOTAL trial (ClinicalTrials.gov iden-
tifier: NCT01685190; A Randomised Phase II Trial of Prostate and
PelvicVersusProstateAloneRadiotherapyTreatmentVolumesUsing
High-Dose IMRT for Locally Advanced Prostate Cancer), currently a
randomized phase II study, or the Radiation Therapy Oncology
Group 0924 phase III trial (ClinicalTrials.gov identifier:
NCT01368588), will establish whether the addition of high-dose
nodal irradiation using intensity-modulated RT improves outcomes
comparedwithprostate-onlyRTinpatientswithN0M0disease. Some
patients, staged clinically as N0, would be found to have pathologic
evidence of lymphnodemetastases if subjected to lymphnode dissec-
tion, and it might be argued that our findings for pelvic RT suggest a
benefit for such treatment inpatientswith clinical orpathologicnode-
positive disease. Alternatively, it is possible that the larger fields used
for pelvic irradiation might actually have achieved better coverage of
the prostate itself, compared with prostate-only fields as used in the
pre–intensity-modulated RT era, and the trends seen could reflect
this. However, our data on local control in the prostate do not permit
further exploration of this possibility here.
As would be expected, our toxicity data indicate a detectable,
although modest, impact of RT as administered in this trial. It is
noteworthy that thegrade3 toxicity thatwedetectedwas short term
only, and we would suggest that the toxicity of RT should not be
regarded as a barrier to its routine use in this patient population.
In this trial, the intendeddurationofADTwas lifelong.Datahave
emergedelsewhereon the long-termtoxicities ofADT,25-27 andweare
unable to provide data regarding optimal duration because of the
symmetry and long-term nature of ADT in both treatment arms of
our study. For high-risk disease, data from clinical studies support
longer ( 2 years) rather than shorter durations ( 6months).5
This trial underlines the benefits of achieving local control with
RT in locally advanced prostate cancer. Surgery might also be an
effective means of achieving local disease control,2,28 but given the
Level I evidence presented here and by others,15 alternatives to
ADTRT should only be administered in the context of a prospective
randomized controlled trial.
Recent data suggest that some men with T3-4 disease are still
beingmanagedwith ADT alone.29,30 Although there are undoubtedly
patients for whomRT or indeed any curative therapy would be inap-
propriate because of age, comorbidity, or other factors, we conclude
that patients with clinically node-negative, locally advanced prostate
cancer who are suitable for additional RT should be offered that
option, an opinion shared by European31 and North American32
guidelines.
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GLOSSARY TERMS
Gleason score: pathologic description of prostate cancer
grade on the basis of the degree of abnormality in the glandular
architecture. Gleason patterns 3, 4, and 5 denote low, intermedi-
ate, and high levels of histologic abnormality and tumor aggres-
siveness, respectively. The score assigns primary and secondary
numbers on the basis of the most common and second most
common patterns identified.
intensity-modulated radiation therapy: radiation
treatment using beams with nonuniform fluence profiles that
shape the dose distribution in the target volume and adjacent
normal structures. Beam modulation is typically achieved via
multileaf collimators or custom-milled compensators to achieve
the appropriate fluence profiles calculated by inverse optimization algo-
rithms. The radiation beam is divided into beamlets of varying intensity
such that the sum from multiple beams via inverse planning results in
improved tumor targeting and normal tissue sparing. A technique of
radiation therapy delivery in which the intensity of each beamlet of radi-
ation coming from a specific angle can be adjusted to provide a desired
dose distribution when the doses delivered from all beamlets are added
from a single angle and from all dose delivery angles. An advanced type
of high-precision radiotherapy, which aims to improve the coverage of
the radiotherapy target and/or minimize radiation dose to surrounding
normal tissue.
overall survival: the duration between randomassignment anddeath.
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